Watch this session on ECR Live: Thursday, March 2, 16:00–17:30, Room X
Imaging data is key in multicentre clinical trials for cancer research but quality control is currently a major impediment, bringing the validity of the trials into question and potentially impacting on the quality of drugs put on the market, a panel of experts will argue today in a session held by the ESR and the European Organisation for Research and Treatment of Cancer (EORTC) at the ECR.
Imaging is increasingly contributing to cancer research thanks to the development of innovative techniques that depict functional and molecular processes. In most oncological clinical trials, imaging is now the primary criteria used to evaluate progression of disease or efficiency of the drug being tested.
The best way to obtain valuable imaging measurements is to involve the imagers who take part in these trials and educate the clinician investigators, experts will explain in the session.
When it comes to imaging in cancer research, a number of issues take centre stage. Difficulties associated with integrating imaging biomarkers into trials have been neglected compared with those relating to the inclusion of tissue and blood biomarkers, largely because of the complexity of imaging technologies, safety issues related to new contrast media, standardisation of image acquisition across multivendor platforms and various post-processing options available with advanced software, as reported recently in The Lancet by the EORTC and leading researchers.